Skip to Content
Merck
CN
  • TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications.

TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications.

Biochemical and biophysical research communications (2003-12-19)
Piotr Zień, Olga Abramczyk, Katarzyna Domańska, Maria Bretner, Ryszard Szyszka
ABSTRACT

Two ATP-competitive inhibitors-4,5,6,7-tetrabromo-benzotriazole (TBBt) and 4,5,6,7-tetrabromo-benzimidazole (TBBz) have been shown to decrease activity of CK2 holoenzyme. Surprisingly it occurs that TBBz contrary to TBBt does not inhibit free catalytic subunit CK2 [Formula: see text]. Both inhibitors are virtually inactive against RAP protein kinase. The above-mentioned protein kinases phosphorylate in vitro a set of acidic ribosomal P-proteins of the 60S ribosomal subunit. Such a modification is one of the mechanisms regulating translational activity of ribosomes in vivo. Application of these two very selective inhibitors allows us to define the role of free catalytic [Formula: see text] subunit of CK2 in phosphorylation of ribosomal proteins. It occurs that CK2 [Formula: see text] but not CK2 holoenzyme is responsible for phosphorylation of P-proteins in vivo. Moreover, elimination of both forms of protein kinase CK2 (hCK2 and CK2 [Formula: see text] ) activity in living cells led to dramatic loss of the translational activity of the ribosome.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Casein Kinase II Inhibitor XII, TBBz